The early and reliable detection of diseases is the basis for a healthy and long life.
protexam is based on the research of the mosaiques group, which was founded in Hanover in 2002. The group's goal is biotechnological research at the highest scientific and clinical level, for the benefit of customers. It is the international market leader in the field of clinical proteome analysis. The company's research and product development stands for the implementation of clinical proteome analysis in practice, the basis of personalized medicine. Mosaiques works with numerous renowned clinics and institutes worldwide. The researcher Prof. Dr. Dr. Harald Mischak is the company founder and member of the management board.
20
_____________________________
years of research
400
_____________________________
scientific publications
100
_____________________________
clinical trials
Milestones from 20 Years of Research
Serviceliste
-
2002Listenelement 1This year, capillary electrophoresis is successfully coupled with mass spectrometry. The mosaiques group is founded.
-
2003Listenelement 2It is shown for the first time that the determination of proteins and peptides in human urine by capillary electrophoresis mass spectrometry is a suitable tool for establishing new diagnostic markers.
-
2005A scientific study is published demonstrating the high stability advantage of urine over blood plasma. Mosaiques applies statistical methods and artificial intelligence to extract and process the relevant information from the multidimensional proteomic data.
-
2006Further research reveals the first disease markers for prostate cancer and bladder cancer.
-
2008The first positive study results for the early detection of heart and kidney diseases are published.
-
2009Initial study results suggest an association between age and kidney disease.
-
2010Recommendations and guidelines for the identification and qualification of biomarkers in clinical proteomic analysis are defined and published.
-
2012The validity of clinical proteomic analysis is established in the context of heart failure.
-
2014The world's first proteome-driven randomized multicenter clinical intervention trial is launched.
-
2016The American Food and Drug Administration (FDA) issues Prof. Dr. Harald Mischak a letter of support to use clinical proteomic analysis in pharmaceutical studies.
-
2017Another breakthrough has been achieved: proteomic analysis can be used to distinguish between different kidney diseases.
-
2018Proteomic analysis can detect a predisposition to cancer at an early stage.
-
2020The first prospective intervention study is published in which therapy was initiated through early detection of diabetic kidney disease using clinical proteomic analysis.
-
2021Biological age can be determined using clinical proteomic analysis and the dynamics of aging can be predicted.
-
2022The prospective multicenter cohort study on the predictive performance and clinical application of the test for the early detection of severe COVID-19 disease has been successfully completed.
-
2023A method for prognosis and personalized in silico prediction of treatment efficacy in cardiovascular and chronic kidney diseases was developed.